Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Denali Therapeutics, with a price target of $32.00.

Andrew Fein has given his Buy rating due to a combination of factors tied to Denali’s differentiated clinical and regulatory posture in Hunter syndrome. He underscores that tividenofusp’s use of a broader “comprehensive HS” biomarker, together with substantial Neurofilament Light reductions and normalization rates, offers a more persuasive link to neuroprotection than a rival program that relied on a narrower surrogate and lacked strong neurodegeneration data.

Fein also highlights that Denali’s evidence package is bolstered by an ongoing randomized, active-comparator Phase 2/3 trial designed to confirm benefit, while the competitor faces regulatory setbacks and safety concerns from AAV vector–related tumorigenicity. In his view, Denali’s non-viral Transport Vehicle platform not only avoids these genomic risks but is positioned to become the standard of care in neuronopathic Hunter syndrome and to support a broader franchise in other lysosomal storage disorders, expanding long-term market opportunity.

In another report released on February 10, Morgan Stanley also maintained a Buy rating on the stock with a $40.00 price target.